Levemir Flexpen (Insulin Detemir)

Insulin detemir binds to insulin receptors on muscle and fat cells, promoting glucose uptake, and suppresses hepatic glucose production. Its fatty‑acid side chain enables reversible binding to albumin, extending its duration of action and delivering a consistent basal insulin effect for up to 24 hours after subcutaneous injection.

The dose of Levemir Flexpen is individualized. A qualified prescriber determines the appropriate amount based on the patient’s age, weight, type of diabetes, current glucose control, and other medications. Patients should follow the dosing instructions provided by their healthcare professional and adjust only under medical supervision.

Safety data for insulin detemir in pregnancy and lactation are limited. Healthcare providers may consider its use when the potential benefit outweighs any risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their obstetrician and diabetes specialist.

To order Levemir Flexpen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details (including cold‑chain handling), and required import documentation.

Levemir Flexpen (insulin detemir) is a long‑acting basal insulin with a relatively flat pharmacokinetic profile, typically lasting up to 24 hours. Compared with insulin glargine, detemir may have a slightly shorter duration, requiring twice‑daily dosing in some patients, but it offers lower variability and less weight gain in certain studies.

Levemir Flexpen should be stored in a refrigerator at 2‑8 °C, protected from light. Do not freeze or shake the pen. Once in use, it may be kept at controlled room temperature (up to 30 °C) for a maximum of 28 days, as indicated on the label, while still protecting it from direct heat and light.

Levemir Flexpen is administered by subcutaneous injection, typically into the abdomen, thigh, or upper arm. The pen provides a pre‑filled, single‑use cartridge that allows precise dose selection. Patients should rotate injection sites to reduce the risk of lipodystrophy and follow the manufacturer’s instructions for proper pen use.

The most serious risks include severe hypoglycaemia, which can cause loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis. Patients should be educated on recognizing early signs of low blood glucose, have a rapid‑acting carbohydrate source available, and seek immediate medical attention if a severe reaction occurs.

Levemir Flexpen should not be used by individuals with a known hypersensitivity to insulin detemir, any of the pen’s excipients, or other insulins. It is also contraindicated in patients experiencing hypoglycaemia unawareness without appropriate medical supervision. Clinicians must evaluate each patient’s medical history before initiating therapy.